Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Lab21, Quidel Expand International Distribution Agreement

Published: Tuesday, February 11, 2014
Last Updated: Tuesday, February 11, 2014
Bookmark and Share
Expanded agreement will see Lab21 distribute AnDiaTec’s Real-Time PCR Tests within the UK.

Lab21 has expanded its existing agreement with Quidel Corporation, through its subsidiary, Microgen Bioproducts Limited. This expands on the previous agreement which has seen Lab21 distribute the QuickVue product range in the UK.

The AnDiaTec product range includes tests that aid in the diagnosis of several infectious diseases including Norovirus, Enterovirus, Epstein Barr Virus, Herpes Simplex, Varicella-Zoster Virus, Chlamydia and Mycobacterium tuberculosis. The previous agreement saw Lab21 distribute Quidel’s QuickVue products which included rapid diagnostics for Chlamydia, H. Pylori, Influenza, Respiratory Syncytial Virus, Streptococcus, and Pregnancy.

Graham Mullis, CEO of Lab21, commented: “We are delighted to expand our distribution partnership with Quidel to include the AnDiaTec molecular product portfolio. Having built a strong reputation in the provision of tests for infectious diseases, this deal will further expand the range of products we are able to offer, strengthening our position as experts in the provision of clinical diagnostics.” 

John Garland, Senior Sales & Marketing Director EMEA, Quidel, commented: “Lab21 has a strong reputation in the provision of excellent clinical diagnostics products. Lab21’s expertise and network with its customer base will be crucial to encouraging the increased uptake of the rapid, accurate and easy to use AnDiaTec Product Range.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novacyt, Lab21 to Combine in Stock-For-Stock Transaction
On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.
Wednesday, May 28, 2014
Lab21 Announces Sale of South Carolina Operations
Company announces sale of its laboratory operations to Reedy Acquisitions Corp.
Tuesday, April 23, 2013
Lab21 and IntegraGen Partner
Lab21 Limited has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
Tuesday, March 05, 2013
Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.
Tuesday, February 26, 2013
BD and Lab21 Collaborate
Both Companies collaborate to develop new oncology assays on the BD MAX™ platform.
Tuesday, October 16, 2012
Clydesdale Bank £5 Million Funding to Support Lab21 International Growth
Lab21 is expected to deliver greater than 30% revenue growth in 2012.
Tuesday, July 10, 2012
Lab21 Partners with Major Pharmaceutical Company to Develop New Companion Diagnostic Assay
Agreement allows Lab21 to develop, manufacture and distribute a new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner's therapeutic monoclonal antibody.
Tuesday, June 26, 2012
Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping
Company to expand its intellectual property portfolio in infectious disease testing.
Monday, May 21, 2012
Lab21 Unveils New Molecular Analysis Services at Greenville Site
The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service.
Monday, May 14, 2012
Lab21 and ITOR Launch Clinical Genomics Center in USA
New Clinical Genomics Center will be located within the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, South Carolina.
Wednesday, March 07, 2012
Lab21 Acquires New Real Time PCR Technology
Company announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits.
Monday, February 27, 2012
Lab21 Acquires New Real Time PCR Technology
Company expects to launch diagnostic assays using PCR technology during first half of 2012.
Wednesday, January 25, 2012
Lab21 Acquires Molecular Diagnostics Company Myconostica
The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays.
Tuesday, May 24, 2011
Lab21 Secures new Patents in Hepatitis C Drug Resistance and Fluorescent Carbon-Based Nanoparticle Technology
New patent refers to technology allowing the genotypic identification of drug resistant mutations in the 4 major global genotypes of HCV.
Thursday, December 09, 2010
Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Lab21 announces an agreement with ITOR to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
Wednesday, October 20, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos